Protara Therapeutics is trading at $2.46, up +5.59%, as the move coincides with broader biotech-sector strength.
- No October 20 company-specific announcement appeared in the news results. The latest identified update was October 15, when Protara announced completion of a trial enrollment phase.
- XBI is up 2.10%, amid sector M&A activity and positive clinical-trial news.
- These are sector-wide factors, not a confirmed company-specific catalyst.